Literature DB >> 2901288

Clonal genomic alterations in glioma malignancy stages.

C D James1, E Carlbom, J P Dumanski, M Hansen, M Nordenskjold, V P Collins, W K Cavenee.   

Abstract

Comparison of constitutional and tumor genotypes at chromosomal loci defined by restriction fragment length alleles has proven useful in determining the genomic position and tissue specificity of recessive mutations that predispose to cancer (Hansen, M.F., and Cavenee, W.K. Cancer Res., 47:5518-5527, 1987). Here we have applied this approach to 53 unrelated patients with glial tumors of varying histological malignancy grade. Loss of constitutional heterozygosity for loci on chromosome 10 was observed in 28 of 29 tumors histologically classified as glioblastoma (malignancy grade IV) whereas no similar losses were observed in any of 22 gliomas of lower malignancy grade. Examination of restriction fragment length alleles on other chromosomes revealed that loss of sequences on chromosomes 13, 17, or 22 had occurred at nonrandom frequencies and in at least one instance of each malignancy grade of adult glioma. The tumors in which loss of constitutional heterozygosity was observed were composed of one or a mixture of glial cell subtypes displaying astrocytic, oligodendrocytic, and/or ependymal differentiation. These results demonstrate a close association of the loss of chromosome 10 sequences with the most malignant histological stage of glioma and that glioblastoma arises as the clonal expansion of an earlier staged precursor. Furthermore they suggest that glioblastoma is a common phenotypic and malignancy terminus for glial tumors of various cellular subtypes which is reached through a common molecular pathway. This approach which involves the identification of malignancy stage specific somatic losses of heterozygosity provides a genotypic, rather than phenotypic, analysis of tumor progression.

Entities:  

Mesh:

Year:  1988        PMID: 2901288

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  100 in total

Review 1.  Molecular genetics of neurological tumours.

Authors:  R Y Chung; B R Seizinger
Journal:  J Med Genet       Date:  1992-06       Impact factor: 6.318

2.  Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis.

Authors:  P H Cogen; L Daneshvar; A K Metzger; G Duyk; M S Edwards; V C Sheffield
Journal:  Am J Hum Genet       Date:  1992-03       Impact factor: 11.025

Review 3.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

4.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.

Authors:  N Sugawa; A J Ekstrand; C D James; V P Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  Loss of heterozygosity on chromosome 1q in human breast cancer.

Authors:  L C Chen; C Dollbaum; H S Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

6.  Loss of heterozygosity for DNA polymorphisms mapping to chromosomes 10 and 17 and prognosis in patients with gliomas.

Authors:  C E Jones; M B Davis; J L Darling; J F Geddes; D G Thomas; A E Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

7.  Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas.

Authors:  F Yamaguchi; H Saya; J M Bruner; R S Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

Review 8.  Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas.

Authors:  R S Morrison; F Yamaguchi; H Saya; J M Bruner; A M Yahanda; L A Donehower; M Berger
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 9.  The application of 5-bromodeoxyuridine in the management of CNS tumors.

Authors:  A Freese; D O'Rourke; K Judy; M J O'Connor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway.

Authors:  R A Gjerset; H Fakhrai; D L Shawler; S Turla; O Dorigo; A Grover-Bardwick; D Mercola; S F Wen; H Collins; H Lin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-03       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.